BacterOMIC Set to Enter Partnering Phase: Scope Fluidics Receives BUY Rating with FV at PLN 230.2psFOREXGPW’s Analytical Coverage Support Programme 3.0
Medicalgorithmics: A Strategic Shift Towards Growth and Innovation in the Medical Technology SectorFOREXGPW’s Analytical Coverage Support Programme 3.0
Marvipol Development: BUY Recommendation and FV of PLN 10.49 per Share (31.2% Upside)FOREXGPW’s Analytical Coverage Support Programme 3.0
ATM Grupa's Core Business Remains Solid Despite Temporary Weakness in Premium Content PipelineSTOCKGPW’s Analytical Coverage Support Programme 3.0
Molecure valuation update: HOLD recommendation, Phase I trials progress, funding concerns, share issue scenarioSTOCKGPW’s Analytical Coverage Support Programme 3.0